Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Naprodis, Inc.
WARNING LETTER
•Naprodis, Inc.•November 22, 2011

Naprodis, Inc. – FDA Warning Letter, Nov 22, 2011

Record Details

The FDA issued a Warning Letter to NAPRODIS, Inc. following an inspection from November 8-22, 2011, and a subsequent review of product labeling and websites (naprodis.com, aromune.com) in March 2012. The FDA determined that the firm's Phybiosis Aromune, Kinarome Oregano Oil, and Kinarome PMS & Menopause Synergy products are promoted with claims that cause them to be unapproved new drugs and misbranded drugs under the Federal Food, Drug, and Cosmetic Act. Specifically, the products are deemed drugs under section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)] due to claims of cure, mitigation, treatment, or prevention of disease, such as "anti-infectious properties" and "for bacterial, viral, fungal, and parasitic infections." These products are also considered "new drugs" under section 201(p) [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their intended uses and lack prior FDA approval as required by section 505(a) [21 U.S.C. § 355(a)]. Furthermore, they are misbranded under section 502(f)(1) [21 U.S.C. § 352(f)(1)] because they are intended for conditions not amenable to self-diagnosis, and adequate directions for use cannot be provided for a layman. The introduction of these misbranded drugs into interstate commerce violates section 301(a) [21 U.S.C. § 331(a)]. NAPRODIS, Inc. is required to take prompt corrective action and notify the FDA in writing within 15 working days, detailing steps taken and providing a timetable for any outstanding corrections. Failure to comply may result in regulatory actions, including product seizure or injunction. The letter also notes that if products are marketed as dietary supplements, they must comply with 21 CFR Part 111 CGMPs, but the therapeutic claims render them drugs.

Company
Naprodis, Inc.
Inspection date
November 22, 2011
Product type
Drugs
Office
Department of Health and Human Services
People
  • Alonza E. Cruse (Director)
  • Ingeborg Small
View Company Profile

ID · 348a5d51-47bc-4f74-8aa7-6f9bfb0e6c46

Violation Codes6
21 U.S.C. 321(g)(1)21 U.S.C. 321(p)21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 CFR 11121 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Naprodis, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.